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Glycosphingolipid depletion in Fabry disease lymphoblasts glycosphingolipids with a-galactosyl linkages, including
with potent inhibitors of glucosylceramide synthase. galabiosylceramide and globotriaosylceramide, as well
Background. Fabry disease is an inherited X-linked disorder as the blood group B and B1 antigenic glycosphingolipidsresulting in the loss of activity of the lysosomal hydrolase
[2]. Globotriaosylceramide is also the receptor for vero-a-galactosidase A and causing the clinical manifestations of
toxin [3]. Globotriaosylceramide accumulates in the af-renal failure, cerebral vascular disease, and myocardial in-
farction. The phenotypic expression of this disorder is manifest fected tissues of Fabry disease, including the kidney,
by the accumulation of glycosphingolipids containing a-gal- vascular endothelium, peripheral nerves, and heart. The
actosyl linkages, most prominently globotriaosylceramide. major clinical manifestations of Fabry disease includeMethods. Based on quantitative structure activity studies,
renal failure, cerebral vascular disease, myocardial in-we recently reported two newly designed glucosylceramide
farction, neuropathic pain, and skin lesions termed angi-synthase inhibitors based on 1-phenyl-2-palmitoylamino-3-pyr-
rolidino-1-propanol (P4). These inhibitors, 49-hydroxy-P4 and okeratomas.
ethylenedioxy-P4, were evaluated for their ability to deplete Glucosylceramide synthase catalyzes the conversion
globotriaosylceramide and other glucosylceramide-based lipids of ceramide to glucosylceramide using uridine diphosphoin Fabry lymphocytes and were compared with N-butyldeoxy-
(UDP)-glucose as a glucose donor [4]. This glycosyltrans-nojirimycin, another reported glucosylceramide synthase inhib-
ferase is a key enzyme in the biosynthesis of glycosphin-itor.
Results. Concentrations as low as 10 nmol/L of 49-hydroxy- golipids because most glycosphingolipids are glucosylc-
P4 and ethylenedioxy-P4 resulted in 70 and 80% depletion, eramide based. A potential strategy for the treatment of
respectively, of globotriaosylceramide, with maximal depletion Fabry disease (or indeed of any other glycosphingolipid
occurring at three days of treatment. There was no impairment
storage disease in which glucosylceramide is the baseof cell growth. In contrast, N-butyldeoxynojirimycin only mini-
cerebroside) is therefore the inhibition of glucosylcera-mally lowered globotriaosylceramide levels, even at concentra-
tions as high as 10 mmol/L. Globotriaosylceramide depletion mide synthase, the earliest glycosylation step in globotri-
was confirmed by the loss of binding of FITC-conjugated vero- aosylceramide synthesis (Fig. 1).
toxin B subunit to the lymphoblasts. The prototypical glucosylceramide synthase inhibitor is
Conclusions. These findings suggest that selective glucosyl- d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-pro-ceramide synthase inhibitors are highly effective in the deple-
panol (PDMP) [5]. Using PDMP as a lead compound,tion of globotriaosylceramide from Fabry cell lines. We suggest
we previously observed that empiric substitutions of athat these compounds have potential therapeutic utility in the
treatment of Fabry disease. palmitoyl group for the fatty acid in amide linkage and
of a pyrrolidino function for the morpholino group re-
sulted in a glucosylceramide synthase inhibitor of sig-
Fabry disease is an inherited X-linked disorder re- nificantly greater potency [6]. This compound 1-phenyl-
sulting in a deficiency of the lysosomal a-galactosidase 2-palmitoylamino-3-pyrrolidino-1-propanol (P4) was ap-
A [1]. This disorder is manifest by the accumulation of proximately 20 times more potent than PDMP when
assayed against a crude cellular homogenate. More re-
cently, we have identified two highly active glucosylcer-Key words: X-linked disorder, globotriaosylceramide, a-galactosidase
A, Fabry cell lines, verotoxin. amide synthase inhibitors based on simple quantitative
structure activity relationships. Phenyl group substitu-Received for publication July 13, 1999
tions yielded 49-hydroxy-1-phenyl-2-palmitoylamino-3-and in revised form September 15, 1999
Accepted for publication September 28, 1999 pyrrolidino-1-propanol (p-OH-P4) and ethylenedioxy-
1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanolÓ 2000 by the International Society of Nephrology
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previously described [8]. The B subunit of verotoxin
(VT1B) was purified by affinity chromatography and
labeled with fluorescein and was dialyzed to remove free
fluorescein, also as described [9].
Glucosylceramide synthase inhibitors were synthe-
sized by the Mannich reaction from 2-N-acylaminoaceto-
phenone, paraformaldehyde, and pyrrolidine, followed
by reduction with sodium borohydride, as detailed pre-
viously [5]. Four enantiomers are produced during the
synthesis. Because only the d-threo enantiomers are ac-
tive in inhibiting the glucosylceramide synthase, resolu-
tion of the active d-threo inhibitors is performed by chiral
chromatography [7].
Cell treatment
Epstein-Barr virus-transformed normal and Fabry lym-
phoblasts were thawed and dispersed into a 50-fold vol-
ume of RPMI-1640 medium supplemented with 10% bo-
vine fetal serum, penicillin (100 U/mL), and streptomycin
(100 U/mL). The cells were collected by centrifugation at
600 3 g for 10 minutes, resuspended in the same medium,
and grown in a 25 cm2 bent-necked flask (Falcon, Meylan,
France) containing 10 mL of the medium.
For a typical study, one-million Fabry lymphoblasts
were plated in a 75 cm2 of bent-necked flask containing
30 mL of the medium and were incubated for 24 hours
before treatment with glucosylceramide synthase inhibi-
tors. The cells were then treated with or without d-threo-
1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4),
d-threo-49-hydroxy-P4 (p-OH-P4), d-threo-39,49-ethylene-
dioxyphenyl-2-palmitoylamino-3-pyrrolidino-1-propanol
(EtDO-P4), or N-butyldeoxynojirimycin (NBDN) for a
defined time period. Each P4 compound was added into
the culture medium as a bovine serum albumin (BSA)
complex, as described previously [5]. In both control and
NBDN treatments, identical amounts of BSA as either
BSA inhibitor or BSA alone were added to the culture
medium. Following inhibitor treatment, the cells were
Fig. 1. Pathway for globotriaosylceramide metabolism. The synthesis
collected by centrifugation at 600 3 g for 10 minutes andof glucosylceramide is blocked by P4, the P4 homologues, and NBDN.
a-Galactosidase A is deficient in Fabry disease resulting in globotriao- washed with 30 mL of cold phosphate-buffered saline
sylceramide accumulation. (PBS). The cells were collected by centrifugation, resus-
pended in 5 mL of cold PBS, and transferred into a glass
tube. The cell suspension was centrifuged for 10 minutes
at 600 3 g. The resultant cell pellet was fixed with 3 mL(EtDO-P4) [7]. These inhibitors are approximately 2000
times more potent than PDMP when similarly assayed. of methanol and 3 mL of chloroform. The cells were
then disrupted in a bath sonicator. After dispersion, theIn this study, we used these novel glucosylceramide syn-
thase inhibitors to test whether globotriaosylceramide mixture stood for 30 minutes at room temperature and
was then centrifuged for 30 minutes at 2000 3 g. Thelevels could be depleted in a transformed lymphoblast
cell line derived from a patient with Fabry disease. supernatant was transferred into a second glass tube.
The remaining residue was mixed with 1 mL of methanol
and 1 mL of chloroform and was briefly sonicated. After
METHODS
a repeat centrifugation, the supernatant was combined
Reagents with the first supernatant. The residue was air dried
and used for determination of the protein content. TheImmortalized B cells, generated and maintained fol-
lowing Epstein-Barr virus transformation, were used as pooled supernatants were mixed with 3.6 mL of 0.9%
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(wt/vol) of NaCl and centrifuged for five minutes at
800 3 g. The chloroform layer was washed with 2 mL
of methanol plus 1.6 mL of 0.9% (wt/vol) NaCl and
centrifuged for five minutes at 800 3 g. The resultant
lower layer was transferred into a glass tube and dried
under a stream of nitrogen. The dried lipids were kept
at 2208C before analysis.
Lipid analysis
The dried lipids were dissolved in chloroform/metha-
nol (95:5), and a fraction was used for the determination
of total phospholipid [10]. The remaining lipids were
dissolved in 2 mL of chloroform and 1 mL 0.21 mol/L
NaOH in methanol and incubated for one hour at room
temperature. The reaction was terminated by the addi-
tion of 0.8 mL of 0.25 N HCl. After centrifugation for
five minutes at 800 3 g, the lower layer was transferred
into a glass tube and mixed with 4 mL of methanol plus
1.6 mL of 0.05 N HCl containing 25 mmol/L HgCl2. The
reaction mixture was incubated for 15 minutes at 378C
and then mixed with 2 mL of chloroform plus 1.6 mL
water. After centrifugation for five minutes at 800 3 g,
the lower layer was washed with 2 mL of methanol plus
1.6 mL of 30 mmol/L ethylenediaminetetraacetic acid
(EDTA; pH 8.0). The lower layer was washed twice with
2 mL of methanol plus 1.6 mL of water. The resultant
lower layer was transferred into another glass tube and
dried down under a stream of nitrogen. The dried hy-
drolyzed lipids were kept at 2208C before analysis.
The dried lipids were dissolved in chloroform/metha-
nol (95:5) and applied to a high-performance thin layer
chromatography plate (Merck, Darmstadt, Germany) to
determine the level of each neutral glycosphingolipid.
Fifty to 70 nmol of total phospholipid were applied to
the plate. The plate was first developed in a solvent
system consisting of chloroform/methanol (98:2) and was
air dried. The plate was then developed in one of two
solvent systems consisting of either chloroform/metha-
nol/acetic acid/water (61:33:3:3) or chloroform/metha- Fig. 2. a-Galactosidase and b-hexaminidase activities in Epstein-Barr
nol/water (60:35:8). These systems separated ceramide virus-transformed normal and Fabry lymphoblasts. Both enzyme activi-
ties were measured as described in the Methods section. (A and B)dihexoside (CDH), globotriaosylceramide [ceramide tri-
These show a-galactosidase and b-hexosaminidase activities, respec-hexoside (CTH)], and globoside (Gb4) and ceramide tively. Symbols are: (m) buffer; (d) normal; (j) Fabry.
monohexoside (CMH) and CDH, respectively. Follow-
ing the second development, the plates were dried and
sprayed with 8% (wt/vol) CuSO4 pentahydrate in water/ sion of the band corresponding to CTH to a new band,methanol/concentrate H3PO4 (60:32:8) and charred for which had the same Rf as that of CDH.15 minutes at 1508C. Densitometry was measured with
a Kodak digital camera connected to a computer and Protein assay
scanned by NIH 1.49 image program. Known amounts of The residue after lipid extraction was dissolved in 5
glucosylceramide or Gb4 were used to obtain a standard to 10 mL of 0.1 N NaOH by using a heating water bath.
curve in each thin layer chromatography analysis. The The protein concentration was determined by use of the
correspondence of individual bands to those of neutral bicinchoninic acid reagent (Pierce, Rockford, IL, USA).
glycosphingolipids was confirmed by orcinol staining. In
a-Galactosidase assayaddition, the treatment of the lipid extract with a-gal-
actosidase from green coffee beans (Sigma Chemical Lymphoblasts were collected by centrifugation for 10
minutes at 600 3 g and washed twice with chilled PBS.Co., St. Louis, MO, USA) resulted in a complete conver-
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Table 1. Effect of P4, P4 homologues, and NBDN on glycosphingolipid levels in Epstein-Barr virus-transformed Fabry lymphoblasts
CMH CDH CTH Gb4
Inhibitor ng/nmol phospholipid
None
24 hours 2.77, 2.74 5.21, 5.68 1.44, 1.76 n.d.
48 hours 3.79, 2.83 5.33, 4.26 3.81, 3.75 2.08, 1.81
72 hours 3.49, 3.41 5.40, 5.51 3.80, 4.37 1.65, 2.17
D-t-p-OH-P4 10 nmol/L
24 hours n.d. 4.37, 3.94 1.32, 1.27 n.d.
48 hours n.d. 1.94, 2.40 2.18, 2.18 1.31, 2.47
72 hours n.d. 1.19, 1.35 1.42, 1.32 1.09, 1.01
D-t-p-OH-P4 100 nmol/L
24 hours n.d. 3.72, 4.67 1.04, 1.34 n.d.
48 hours n.d. 1.68, 2.10 1.45, 1.30 1.05, 0.94
72 hours n.d. 1.18, 1.39 0.45, 1.01 0.67, 0.58
D-t-p-EtDO-P4 10 nmol/L
24 hours n.d. 3.86, 4.06 1.07, 1.34 n.d.
48 hours n.d. 1.71, 1.31 1.28, 1.23 1.05, 0.83
72 hours n.d. 0.38, 0.35 0.53, 0.41 0.48, 0.40
D-t-p-EtDO-P4 100 nmol/L
24 hours n.d. 3.99, 3.82 1.15, 1.13 n.d.
48 hours n.d. 1.13, 1.42 0.99, 1.06 0.82, 0.83
72 hours n.d. 0.38, 0.19 0.55, 0.51 0.46, 0.61
NBDN 10 nmol/L
24 hours 2.47, 2.59 3.93, 3.85 1.58, 1.45 n.d.
48 hours 2.89, 2.73 4.64, 3.34 3.19, 2.68 1.87, 1.43
72 hours 2.90, 3.19 4.12, 4.56 3.42, 3.62 1.56, 1.44
NBDN 10 mmol/L
24 hours 1.30, 1.47 2.91, 2.88 1.55, 1.38 n.d.
48 hours 2.24, 1.73 2.50, 2.88 2.48, 2.15 1.52, 1.44
72 hours 1.83, 2.69 2.34, 3.84 2.43, 3.45 1.44, 1.60
The lipids were extracted, subjected to alkaline methanolysis and acid hydrolysis, and dried under nitrogen as previously employed. The dried lipids were dissolved
in chloroform:methanol (95:5) and applied to a high performance thin layer chromatography plate in an amount equivalent to 50 to 70 nmol of phospholipid
phosphate. The plate was first developed in a solvent system consisting of chloroform:methanol (98:2) and air dried. For analysis of CDH, CTH and Gb4 plates were
developed in a second solvent system consisting of chloroform:methanol:acetic acid:water (61:33:3:3). CMH was analyzed by development in cloroform:methanol:water
(60:35:8). Plates were sprayed with cupric sulfate reagent, charred, and the lipids quantitated by densitometry. n.d. denotes not detectable.
The cellular pellet was suspended in 3 mg/mL sodium of 250 mL of 0.2 mol/L Na2CO3. The product p-nitrophe-
nol was measured as described previously in this article.taurocholate and 28 mmol/L citric acid/44 mmol/L
Na2HPO4 (pH 4.4) and sonicated for 10 seconds three
Labeling Epstein-Barr virus transformed Fabrytimes with a probe-type sonicator in a ice water bath.
lymphoblasts with FITC-conjugated verotoxinThe cell homogenate was centrifuged for 30 minutes at
20,000 3 g at 48C. The resultant supernatant was used Fabry lymphoblasts were treated with or without 50
nmol/L p-OH-P4 for three days as described earlier inas an enzyme source for a-galactosidase [11] and
b-hexosaminidase assays [11]. this article. After inhibitor treatment, the cells were col-
lected by centrifugation at 600 3 g for 10 minutes, sus-a-Galactosidase was assayed in a total volume of 600
mL. The reaction mixture consisted of 5 mmol/L p-nitro- pended in 10 mL of chilled PBS, and mixed with 25 mL
of chilled PBS. The cells were collected by centrifugationphenyl-a-galactopyranoside, 28 mmol/L citric acid/44
mmol/L Na2HPO4 (pH 4.4), 5 mg/mL BSA, and 500 at 600 3 g for 10 minutes, resuspended in 3 mL of chilled
PBS, and counted with a hemacytometer. One millionng/mL of protein of the supernatant. The reaction was
initiated by the addition of the cell supernatant, kept at cells in 150 mL of PBS were incubated with 50 mL of PBS
or 50 mL of PBS containing 200 mg/mL FITC-conjugated378C for 10, 30, and 90 minutes, and terminated by adding
600 mL of 0.2 mol/L Na2CO3. The product, p-nitrophenol, verotoxin B (FITC-VTB) for 40 minutes at room temper-
ature. The reaction tube was wrapped with aluminumwas measured by the absorbence at 400 nm (e400: 18,300
at pH 9 to 10). b-Hexosaminidase was assayed in a total foil and inverted five times gently every five minutes.
The cells were washed three times with 3 mL of PBSvolume of 250 mL. The reaction mixture consisted of 1
mmol/L p-nitro-phenyl-b-glucosamine, 30 mmol/L so- and centrifuged at 4000 r.p.m. for five minutes. The pellet
was resuspended in 0.5 mL of PBS for subsequent cyto-dium citrate (pH 4.5), 0.1% (wt/vol) Triton 100-X, and
24 ng/mL of supernatant protein. The reaction was initi- metric analysis on a Coulter Elite ESP. Unlabeled cells
were used for initial light scatter analysis, and the per-ated by the addition of the supernatant, kept at 378C for
5, 10, 20, and 30 minutes, and terminated by the addition centage of cells with specific staining by FITC-VTB was
Abe et al: Glycosphingolipid depletion in Fabry disease450
Fig. 3. Effects of P4 derivatives and NBDN
on neutral glycosphingolipid level in Epstein-
Barr virus-transformed Fabry lymphoblasts.
(A) This shows a representative thin layer chro-
matogram of lymphoblast following inhibitor
treatment for two days. The plate was devel-
oped in a two-step solvent system consisting of
chloroform/methanol (98:2) as the first devel-
opment and chloroform/methanol/acetic acid/
water (61:33:3:3) as the second development.
The lipids were visualized by charring, as de-
scribed in the Methods section. Abbreviations
are: CMH, ceramide monohexoside; CDH,
ceramide dihexoside; CTH, ceramide trihexo-
side; Gb4, globoside; and SM, sphingomyelin.
defined by positioning cursors on the basis of the un- are much greater than that of P4 [7]. Recently NBDN,
stained control cells. The data were collected on a 4 a nonspecific inhibitor of glucosylceramide synthase, has
decade log 10 scale of increasing fluorescence intensity. been reported to have limited efficacy in decreasing gly-
Ten thousand cells were analyzed for each sample. cosphingolipid levels in tissues of knockout mice with
Tay-Sachs and Sandhoff diseases phenotypes [12, 13].
We therefore compared the effects of these inhibitorsRESULTS
on protein, phospholipid, and neutral glycosphingolipidEpstein-Barr virus transformed normal and
contents of Fabry lymphocytes.Fabry lymphoblasts
There was no significant difference in protein and
Lysosomal enzyme activities were measured in control phospholipid content between untreated and treated
and Fabry-transformed lymphoblasts. The total a-gal- cells with any of the inhibitors at each time point studied.
actosidase activity in Epstein-Barr virally transformed Under all conditions, lymphocytic aggregations were
Fabry lymphoblasts was significantly lower than that of preserved and were microscopically similar, indicatingtransformed normal lymphoblasts (Fig. 2A). By contrast,
that these inhibitors do not inhibit cell growth under the
b-hexosaminidase activity, a typical lysosomal enzyme,
conditions employed.was detected and comparable in both cell lines (Fig. 2B).
Ceramide dihexoside, globotriaosylceramide (CTH),Because the assay employed for lysosomal a-galacto-
and Gb4 contents in Fabry lymphocytes were significantlysidase measures both A and B isoforms, most of the lyso-
reduced by treatment of the cells with p-OH-P4 andsomal a-galactosidase activity in the normal lymphoblasts
EtDO-P4 over three days (Table 1 and Fig. 3A). Mostis of the A isoform. Therefore, the lysosomal a-galac-
of glucosylceramide in the Fabry cells disappeared withintosidase deficiency was specific to the Fabry lymphoblast.
24 hours of treatment with both P4 homologues. CTHThese cells were thus used for the subsequent studies.
levels, reflective of globotriaosylceramide, decreased by
Effects of P4, P4 derivatives, and approximately 70 and 80% of control values, with 10
N-butyldeoxynojirimycin on Epstein-Barr nmol/L and 100 nmol/L p-OH-P4, respectively, by the
virus-transformed Fabry lymphoblasts third day of treatment. A 90% decrease in CTH levels
was observed following treatment with 10 or 100 nmol/LA previous study showed that inhibitory effects of
p-OH-P4 and EtDO-P4 on glucosylceramide synthase EtDO-P4. These results indicate EtDO-P4 is slightly
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Fig. 3. Continued. (B) This denotes the time-
dependent changes in ceramide dihexoside
(s), ceramide trihexoside (globotriaosylcera-
mide; d), and globoside (n) as a percentage of
control glycosphingolipids. Glucosylceramide
levels (CMH, h) are only shown for NBDN
in which both 10 nmol/L and 10 mmol/L incu-
bations only partially depleted the cerebro-
side.
more potent than p-OH-P4 as an inhibitor of neutral In addition, a reduction in CDH or CTH was observed.
However, the depletion of the cerebroside and moreglycosphingolipid synthesis (Fig. 3B).
On the other hand, NBDN was significantly less potent highly glycosylated lipids was obviously weaker than
that observed in the presence of 50 nmol/L p-OH-P4in the reduction of neutral glycosphingolipids when com-
pared with P4 or the P4 homologues. Concentrations (Table 2).
To confirm that globotriaosylceramide was signifi-as high as 10 mmol/L NBDN were less potent than 10
nmol/L of the P4 homologues and, surprisingly, did not cantly depleted, cells were labeled with FITC-conjugated
verotoxin and analyzed by flow cytometry. Two popula-completely deplete the lymphoblasts of their glucosylcer-
amide. A second set of determinations was therefore tions of cells were identified, those with high affinity
binding and those with binding, which was only slightlyperformed with higher NBDN concentrations. When the
Fabry lymphoblasts were treated with 100 mmol/L greater than the autofluorescence observed in the ab-
sence of FITC-verotoxin. Treatment for 48 hours withNBDN, the glucosylceramide content was undetectable.
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Table 2. Effects of high dose NBDN and D-threo-p-OH-P4 on
neutral glycosphingolipid levels in Fabry lymphoblasts
CMH CDH CTH
ng/nmol phospholipidInhibitor
None 3.48, 4.07, 3.72 8.31, 8.20, 6.72 7.62, 7.66, 6.53
NBDN
10 mmol 1.96, 2.31 5.00, 4.65 5.09, 5.38
100 mmol n.d., n.d. 2.95, 3.26 4.01, 2.83
D-threo-p-PH-P4
50 nmol n.d. 1.77 2.13
Fabry lymphoblasts were treated for 72 hours with each inhibitor. ND denotes
not detectable.
50 nmol/L p-OH-P4 totally eliminated the high-affinity
binding of the fluorescent marker to the lymphoblasts
(Fig. 4). However, the low-affinity binding was not af-
fected.
DISCUSSION
Although other inherited sphingolipidoses such as
Gaucher disease have been the focus of intense programs
in therapeutics, Fabry disease remains comparatively un-
derstudied. As a result, only limited reports have been
published on potential enzyme replacement therapy or
gene therapy [8, 14]. An alternative strategy for treating
sphingolipid storage diseases is the pharmacological inhi-
bition of key enzymes in the synthesis of the Fabry gly-
cosphingolipids. Recent reports have provided some sup-
port for approaching glycosphingolipid storage disorders
Fig. 4. Effect of D-threo-p-OH-P4 on globotriaosylceramide expres-with substrate depletion. sion by Fabry lymphocytes. Flow cytometric analysis of human Fabry
lymphocytes treated with 50 nmol/L D-threo-p-OH-P4 ( p-OH-P4) forN-butyldeoxynojirimycin, originally developed as a
three days. (A) Unstained control lymphocytes. Specific staining withpotential antiviral agent for HIV infections based on its
FITC-VTB was assigned as a fluorescence intensity greater than 95%
ability to inhibit a-glucosidase, was also identified as a of the unstained control cells. (B) Untreated lymphocytes incubated
with FITC-VTB for 40 minutes. Approximately 80% of cells wereweak inhibitor of glucosylceramide synthase [15]. The
stained with VTB, which is used as a marker of globotriaosylceramideIC50 for the glucosylceramide synthase inhibition occurs expression. Of the total stained cells, 47% are in the second peak with
in the mid-micromolar range. Nevertheless, when fed to a log greater fluorescence intensity than the control unstained cells.
(C ) Lymphocytes treated for three days with p-OH-P4 and incubatedknockout mice lacking b-hexosaminidase A (Tay-Sachs
with FITC-VTB. The fluorescence of the second, high-intensity peakphenotype) or b-hexosaminidase B (Sandhoff pheno- of cells is completely eliminated by p-OH-P4, demonstrating inhibition
type), NBDN partially corrected the phenotype in each of globotriaosylceramide expression.
of these models and prevented ganglioside GM2 accumu-
lation [12, 13]. The use of “experimental epistasis” pro-
vides additional proof of concept for the substrate-deple-
tion strategy. When b-hexosaminidase B-deficient mice duces cell growth arrest and, at sufficiently high concen-
were crossed with those lacking GalNAc transferase, trations, apoptosis. The growth inhibitory effects have
GM2 accumulation was prevented and a normal pheno- been demonstrated to be the result of ceramide accumu-
type ensued [16]. lation [17]. Although originally thought to be the result
The low inhibitory activity against the glucosylceramide of substrate accumulation, the PDMP-induced increase
synthase and its potential toxicities limit the potential use in cell ceramide results from the inhibition of a second
of NBDN in substrate-depletion therapy. PDMP, the par- metabolic pathway. This pathway is the acylation of cera-
ent compound of the inhibitors used in these studies, is mide at the 1-hydroxyl of ceramide and is catalyzed by
comparably active when compared with NBDN. Al- an acidic phospholipase A2 with transacylase activity
[18, 19].though it lacks activity against a-glucosidase, PDMP in-
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Although the inhibitory effects of PDMP on the gluco- In summary, we have begun to evaluate the potential
of applying a substrate depletion strategy to the treat-sylceramide synthase and transacylase are comparable
ment of Fabry disease. By using transformed lympho-with regard to their IC50s, P4 is significantly more active
blasts from a patient with Fabry disease, it can be shownagainst the glucosylceramide synthase. Thus, it has been
that short-term incubations with potent inhibitors of glu-possible to design and screen new inhibitors that can
cosylceramide synthase result in a significant depletionblock glucosylceramide formation in the mid- to low-
of globotriaosylceramide. More convincing proof of con-nanomolar range, but that are relatively inactive against
cept will require the use of suitable in vivo models.the transacylase and therefore do not inhibit cell growth.
The p-OH-P4 and EtDO-P4 homologues are two such
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